Clinical trials: Dasatinib
Solid Tumors
Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors
Background: Bevacizumab inhibits blood vessel growth in cancer cells by blocking a growth factor called VEGF. Dasatinib inhibits the action of proteins called tyrosine kinases, which promote and stimulate blood vessel formation…
- Trial name
- NCT01445509
- Testing
- Bevacizumab, Dasatinib
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
The study is designed to compare the efficacy of asciminib 80 mg QD versus Investigator selected Tyrosine Kinase Inhibitor (TKI) for the treatment of newly diagnosed, previously untreated patients with Ph+ CML-CP.
- Trial name
- NCT04971226
- Testing
- Imatinib, Nilotinib, Bosutinib
- Where
- 110 sites in United States, Australia and 27 more
- Volunteers
- 405 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia, BCR-ABL1 Positive
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
This randomized phase IIB trial studies imatinib mesylate at two different doses and dasatinib to see how well they work in treating patients with previously untreated chronic phase chronic myelogenous leukemia.
- Trial name
- NCT00070499
- Testing
- Dasatinib, Imatinib Mesylate, Laboratory Biomarker Analysis
- Where
- 340 sites in United States, Canada
- Volunteers
- 406 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
This phase II trial tests how well giving dasatinib and quercetin with cyclophosphamide, fludarabine and chimeric antigen receptor (CAR)-T cell therapy works in treating patients with multiple myeloma that has come back after a…
- Trial name
- NCT06940297
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Mayo Clinic
Chronic Phase Chronic Myelogenous Leukemia
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
This is a single arm phase II study that will enroll a minimum of 47 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have previously attempted to…
- Trial name
- NCT04838041
- Testing
- Asciminib 40 MG, Asciminib 40 MG Twice Daily, Asciminib 80 MG daily
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- Medical College of Wisconsin
Aging, Cognitive Decline
Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study
The purpose of this research study is to explore ways to improve motor, cognitive and immune functions for aging adults using multiple techniques like lifestyle changes and risk factor management, as well as medications and…
- Conditions
- Aging, Cognitive Decline, Older Adults, Cardiovascular
- Trial name
- FOES (NCT07000734)
- Testing
- Risk managment, Dasatinib, Quercetin (dietary supplement)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Washington University School of Medicine
Chronic Myeloid Leukemia
Frontline Asciminib Combination in Chronic Phase CML
Adult male and female patients with newly diagnosed Philadelphia chromosome positive (Ph+) and/or BCR-ABL1 positive CML can be included in the study until 3 months after diagnosis.
- Trial name
- CMLXI (NCT03906292)
- Testing
- Imatinib, Nilotinib 300 mg, Dasatinib
- Where
- 21 sites in Germany
- Volunteers
- 125 people
- Sponsor
- University of Jena
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
This is a clinical trial testing whether the addition of one of two chemotherapy agents, dasatinib or venetoclax, can improve outcomes for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia and…
- Conditions
- T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia
- Trial name
- NCT06390319
- Testing
- Dexamethasone, Vincristine, Daunorubicin
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
This phase II trial studies the side effects and how well blinatumomab and combination chemotherapy or dasatinib, prednisone, and blinatumomab work in treating older patients with acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent Acute Lymphoblastic Leukemia
- Trial name
- NCT02143414
- Testing
- Biopsy Procedure, Biospecimen Collection, Blinatumomab
- Where
- 195 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections
Dasatinib for HIV-1 Reservoir Reduction
This study will test if the medicine dasatinib can lower the hidden amount of HIV in the body, called the HIV "reservoir." It will also check if dasatinib is safe and easy to take for people living with HIV who have a suppressed…
- Trial name
- NCT07342491
- Testing
- Dasatinib
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acute Lymphoblastic Leukemia, Pediatric
Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
Very high-risk acute lymphoblastic leukemia
- Trial name
- VHR ALL (NCT06257394)
- Testing
- Dasatinib(Sprycel) arm, Non-Dasatinib(Sprycel) arm
- Where
- 10 sites in South Korea
- Volunteers
- 74 people
- Sponsor
- Hyoung Jin Kang
Chronic Myelogenous Leukemia - Chronic Phase
A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
This CML disease registry (ASC4REAL-2) aims to gather evidence on the tolerability, safety, effectiveness, and patient-reported outcomes (PRO) in real-world healthcare from patients with Ph+-CML-CP treated with TKIs approved for…
- Trial name
- ASC4REAL-2 (NCT07091019)
- Testing
- TKIs
- Where
- 17 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Novartis Pharmaceuticals
Mild Cognitive Impairment, Alzheimer Disease
ALSENLITE: Senolytics for Alzheimer's Disease
This study is being done to evaluate the safety and feasibility of using Dasatinib and Quercetin together in subjects with Mild Cognitive Impairment (MCI) or Alzheimer's disease.
- Trial name
- NCT04785300
- Testing
- Dasatinib, Quercetin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Acute Lymphoblastic Leukemia, Pediatric
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymphocyte.
- Trial name
- NCT03020030
- Testing
- Pegaspargase, Erwinia asparaginase, Cyclophosphamide
- Where
- 9 sites in United States, Canada
- Volunteers
- 560 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
This is a Phase II clinical trial testing the use of two antigen-directed therapies, inotuzumab and blinatumomab, as part of induction therapy for children and young adults with newly diagnosed B-cell precursor acute…
- Trial name
- NCT06533748
- Testing
- Dexamethasone, Vincristine, Inotuzumab
- Where
- 3 sites in United States
- Volunteers
- 128 people
- Sponsor
- St. Jude Children's Research Hospital
Chronic Myelogenous Leukemia, BCR/ABL Positive
OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)
This protocol is a multicentric interventional phase II study from the French CML Intergroup (FILMC). The core of the protocol is to explore the efficacy and safety of an optimization strategy consisting in the modulation of the…
- Trial name
- OPTIM-DASA (NCT01916785)
- Testing
- Dasatinib
- Where
- 34 sites in Canada, France
- Volunteers
- 289 people
- Sponsor
- Versailles Hospital
Acute Lymphoblastic Leukemia
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
The purpose of this study is to test the safety of a new combination of three oral drugs in Ph+ ALL. These drugs are dexamethasone, dasatinib, and ruxolitinib. All three drugs have been studied before in humans.
- Trial name
- NCT02494882
- Testing
- Ruxolitinib, Dasatinib, Dexamethasone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Asciminib Roll-over Study
This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment
- Trial name
- NCT04877522
- Testing
- Asciminib single agent, Imatinib, Nilotinib
- Where
- 85 sites in United States, Argentina and 27 more
- Volunteers
- 347 people
- Sponsor
- Novartis Pharmaceuticals
Recent HIV-1 Infection
Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection
Study to evaluate the safety, tolerability and antiretroviral activity of a new therapeutic strategy, based on the administration of dasatinib, an ITK, in patients with recent (3-12 months) asymptomatic HIV-1 infection.
- Trial name
- DASAHIVCURE (NCT05527418)
- Testing
- Dasatinib
- Where
- Spain
- Volunteers
- 24 people
- Sponsor
- Eva Bonfill
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
The overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific genomic features and targeted treatment approaches to improve the cure rate and quality of…
- Trial name
- NCT03117751
- Testing
- Prednisone, Vincristine, Daunorubicin
- Where
- 8 sites in United States, Australia
- Volunteers
- 790 people
- Sponsor
- St. Jude Children's Research Hospital